Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy.

Literature DB >> 24816173

Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy.

Tarik Asselah¹.

Abstract

Entities: Chemical Disease

Keywords: Daclatasvir; Direct-acting antivirals; Faldaprevir; Simeprevir; Sofosbuvir

Mesh：

Substances：

Year: 2014 PMID： 24816173 DOI： 10.1016/j.jhep.2014.04.042

Source DB: PubMed Journal: J Hepatol ISSN： 0168-8278 Impact factor: 25.083

Keyword Cloud
Cited

× No keyword cloud information.

12 in total

1. Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study.

Authors: Ahmed A Ezat; Abdo A Elfiky; Wael M Elshemey; Noha A Saleh
Journal: Virusdisease Date: 2019-03-21

2. The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease.

Authors: Jim Young; Nina Weis; Harald Hofer; William Irving; Ola Weiland; Emiliano Giostra; Juan Manuel Pascasio; Lluis Castells; Martin Prieto; Roelien Postema; Cinira Lefevre; David Evans; Heiner C Bucher; Jose Luis Calleja
Journal: BMC Infect Dis Date: 2017-01-07 Impact factor: 3.090

3. Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens.

Authors: Jianhong Chen; Xiaxia Zhang; Hao Luo; Chihong Wu; Min Yu; Dan Liu; Hongli Xi; Yihang Zhou; Yaoyu An; Xiaoyuan Xu
Journal: Oncotarget Date: 2017-06-28

4. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection.

Authors: Ossama A Ahmed; Mohamed A Elsebaey; Mohamed Hassan A Fouad; Heba Elashry; Ahmed I Elshafie; Ahmed A Elhadidy; Noha E Esheba; Mohammed H Elnaggar; Shaimaa Soliman; Sherief Abd-Elsalam
Journal: Infect Drug Resist Date: 2018-03-28 Impact factor: 4.003

Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy.

1. Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study.

2. The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease.

3. Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens.

4. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection.

5. Molecular dynamics simulation revealed binding of nucleotide inhibitors to ZIKV polymerase over 444 nanoseconds.

6. Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis.

7. Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus.

Review 8. Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C.

9. Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir.

Review 10. The new era of hepatitis C virus therapy.